Infant Bacterial Therapeutics AB (publ) (IBT-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Infant Bacterial Therapeutics AB (publ) (IBT-B) has a cash flow conversion efficiency ratio of -0.420x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-52.25 Million ≈ $-5.62 Million USD) by net assets (Skr124.36 Million ≈ $13.38 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Infant Bacterial Therapeutics AB (publ) market cap and net worth for the company's overall valuation and market capitalisation.
Infant Bacterial Therapeutics AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Infant Bacterial Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Infant Bacterial Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Infant Bacterial Therapeutics AB (publ) ranked by their cash flow conversion efficiency. Explore Infant Bacterial Therapeutics AB (publ) cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Platform Group AG
XETRA:TPG
|
0.113x |
|
Paradigm Biopharmaceuticals Ltd
AU:PAR
|
-3.276x |
|
Aifeex Nexus Acquisition Corporation
NASDAQ:AIFE
|
-0.002x |
|
Maronan Metals Ltd
AU:MMA
|
-0.179x |
|
Visaka Industries Limited
NSE:VISAKAIND
|
0.060x |
|
Havila Kystruten AS
OL:HKY
|
-0.034x |
|
NanoenTekInc
KQ:039860
|
0.031x |
|
KHD Humboldt Wedag International AG
XETRA:KWG
|
0.191x |
Annual Cash Flow Conversion Efficiency for Infant Bacterial Therapeutics AB (publ) (2014–2024)
The table below shows the annual cash flow conversion efficiency of Infant Bacterial Therapeutics AB (publ) from 2014 to 2024. View latest Infant Bacterial Therapeutics AB (publ) stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr170.26 Million ≈ $18.32 Million |
Skr-113.13 Million ≈ $-12.17 Million |
-0.664x | -100.32% |
| 2023-12-31 | Skr305.15 Million ≈ $32.84 Million |
Skr-101.22 Million ≈ $-10.89 Million |
-0.332x | -28.24% |
| 2022-12-31 | Skr331.71 Million ≈ $35.70 Million |
Skr-85.80 Million ≈ $-9.23 Million |
-0.259x | -83.79% |
| 2021-12-31 | Skr395.25 Million ≈ $42.54 Million |
Skr-55.62 Million ≈ $-5.99 Million |
-0.141x | -6.08% |
| 2020-12-31 | Skr440.15 Million ≈ $47.37 Million |
Skr-58.39 Million ≈ $-6.28 Million |
-0.133x | -31.98% |
| 2019-12-31 | Skr510.40 Million ≈ $54.93 Million |
Skr-51.30 Million ≈ $-5.52 Million |
-0.101x | -18.03% |
| 2018-12-31 | Skr556.72 Million ≈ $59.91 Million |
Skr-47.41 Million ≈ $-5.10 Million |
-0.085x | +58.75% |
| 2017-12-31 | Skr168.37 Million ≈ $18.12 Million |
Skr-34.76 Million ≈ $-3.74 Million |
-0.206x | +45.34% |
| 2016-12-31 | Skr105.23 Million ≈ $11.32 Million |
Skr-39.75 Million ≈ $-4.28 Million |
-0.378x | -65.99% |
| 2015-12-31 | Skr74.81 Million ≈ $8.05 Million |
Skr-17.02 Million ≈ $-1.83 Million |
-0.228x | +33.45% |
| 2014-12-31 | Skr11.03 Million ≈ $1.19 Million |
Skr-3.77 Million ≈ $-405.93K |
-0.342x | -- |
About Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also develop… Read more